Goldman Michel
Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, 1180 Brussels, Belgium.
J Clin Med. 2022 Feb 25;11(5):1248. doi: 10.3390/jcm11051248.
The opinion I put forward in this paper is that attention must continue to be paid to clinical observations compatible with a detrimental effect of anti-SARS-CoV-2 in certain diseases of immunological nature. Using the example of the atypical thrombocytopenic thromboses caused by adenoviral-vector-based vaccines, I argue that usual post-marketing pharmacovigilance programs may fail in identifying very rare vaccine-related disorders. Since the robust protective immunity induced by mRNA vaccines is related to their distinct capacity to induce strong stimulation of T follicular helper cells, I suggest that the safety of mRNA vaccines should be further assessed by appropriately designed epidemiological and mechanistic studies focusing on lymphoproliferative and autoimmune diseases in which T follicular helper cells were found to play a key role.
我在本文中提出的观点是，必须继续关注与抗SARS-CoV-2在某些免疫性疾病中的有害作用相符的临床观察结果。以腺病毒载体疫苗引起的非典型血小板减少性血栓形成为例，我认为常规的上市后药物警戒计划可能无法识别非常罕见的疫苗相关疾病。由于mRNA疫苗诱导的强大保护性免疫与其诱导T滤泡辅助细胞强烈刺激的独特能力有关，我建议通过适当设计的流行病学和机制研究进一步评估mRNA疫苗的安全性，这些研究聚焦于发现T滤泡辅助细胞起关键作用的淋巴增殖性和自身免疫性疾病。
